AAAAAA
Results: 1-25/40
Authors:
Restifo, NP
Citation: Np. Restifo, Hierarchy, tolerance, and dominance in the antitumor T-cell response - Commentary, J IMMUNOTH, 24(3), 2001, pp. 193-194
Authors:
Overwijk, WW
Restifo, NP
Citation: Ww. Overwijk et Np. Restifo, Creating therapeutic cancer vaccines: notes from the battlefield, TRENDS IMMU, 22(1), 2001, pp. 5-7
Authors:
Restifo, NP
Citation: Np. Restifo, Vaccines to die for, NAT BIOTECH, 19(6), 2001, pp. 527-528
Authors:
Restifo, NP
Citation: Np. Restifo, Countering the 'counterattack' hypothesis, NAT MED, 7(3), 2001, pp. 259-259
Authors:
van Elsas, A
Sutmuller, RPM
Hurwitz, AA
Ziskin, J
Villasenor, J
Medema, JP
Overwijk, W
Restifo, NP
Melief, CJM
Offringa, R
Allison, JP
Citation: A. Van Elsas et al., Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy, J EXP MED, 194(4), 2001, pp. 481-489
Authors:
Touloukian, CE
Leitner, WW
Robbins, PF
Rosenberg, SA
Restifo, NP
Citation: Ce. Touloukian et al., Mining the melanosome for tumor vaccine targets: P. polypeptide is a noveltumor-associated, CANCER RES, 61(22), 2001, pp. 8100-8104
Authors:
Kershaw, MH
Hsu, C
Mondesire, W
Parker, LL
Wang, G
Overwijk, WW
Lapointe, R
Yang, JC
Wang, RF
Restifo, NP
Hwu, P
Citation: Mh. Kershaw et al., Immunization against endogenous retroviral tumor-associated antigens, CANCER RES, 61(21), 2001, pp. 7920-7924
Authors:
Kaufman, HL
Rao, JB
Irivine, KR
Bronte, V
Rosenberg, SA
Restifo, NP
Citation: Hl. Kaufman et al., Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model (vol 22, pg 489, 1999), J IMMUNOTH, 23(4), 2000, pp. 509-509
Authors:
Overwijk, WW
Theoret, MR
Restifo, NP
Citation: Ww. Overwijk et al., The future of interleukin-2: Enhancing therapeutic anticancer vaccines, CA J SCI AM, 6, 2000, pp. S76-S80
Authors:
Lee, K
Overwijk, WW
O'Toole, M
Swiniarski, H
Restifo, NP
Dorner, AJ
Wolf, SF
Sturmhoefel, K
Citation: K. Lee et al., Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses, J INTERF CY, 20(6), 2000, pp. 589-596
Authors:
Restifo, NP
Citation: Np. Restifo, Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape, NAT MED, 6(5), 2000, pp. 493-495
Authors:
Overwijk, WW
Restifo, NP
Citation: Ww. Overwijk et Np. Restifo, Autoimmunity and the immunotherapy of cancer: Targeting the "self" to destroy the "other", CR R IMMUN, 20(6), 2000, pp. 433-450
Authors:
Restifo, NP
Ying, H
Hwang, L
Leitner, WW
Citation: Np. Restifo et al., The promise of nucleic acid vaccines, GENE THER, 7(2), 2000, pp. 89-92
Authors:
Restifo, NP
Citation: Np. Restifo, Building better vaccines: how apoptotic cell death can induce inflammationand activate innate and adaptive immunity, CURR OP IM, 12(5), 2000, pp. 597-603
Authors:
Charles, LG
Xie, YC
Restifo, NP
Roessler, B
Sanda, MG
Citation: Lg. Charles et al., Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development, WORLD J URO, 18(2), 2000, pp. 136-142
Authors:
Xiang, R
Lode, HN
Chao, TH
Ruehlmann, JM
Dolman, CS
Rodriguez, F
Whitton, JL
Overwijk, WW
Restifo, NP
Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma (vol. 97, pg. 5492, 2000), P NAS US, 97(23), 2000, pp. 12932-12932
Authors:
Xiang, R
Lode, HN
Chao, TH
Ruehlmann, JM
Dolman, CS
Rodriguez, F
Whitton, JL
Overwijk, WW
Restifo, NP
Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma, P NAS US, 97(10), 2000, pp. 5492-5497
Authors:
Zeng, G
Touloukian, CE
Wang, X
Restifo, NP
Rosenberg, SA
Wang, RF
Citation: G. Zeng et al., Identification of CD4(+) T cell epitopes from NY-ESO-1 presented by HLA-DRmolecules, J IMMUNOL, 165(2), 2000, pp. 1153-1159
Authors:
Touloukian, CE
Leitner, WW
Topalian, SL
Li, YF
Robbins, PF
Rosenberg, SA
Restifo, NP
Citation: Ce. Touloukian et al., Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice, J IMMUNOL, 164(7), 2000, pp. 3535-3542
Authors:
Surman, DR
Dudley, ME
Overwijk, WW
Restifo, NP
Citation: Dr. Surman et al., CD4(+) T cell control of CD8(+) T cell reactivity to a model tumor antigen, J IMMUNOL, 164(2), 2000, pp. 562-565
Authors:
Colella, TA
Bullock, TNJ
Russell, LB
Mullins, DW
Overwijk, WW
Luckey, CJ
Pierce, RA
Restifo, NP
Engelhard, VH
Citation: Ta. Colella et al., Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy, J EXP MED, 191(7), 2000, pp. 1221-1231
Authors:
Feldman, AL
Restifo, NP
Alexander, HR
Bartlett, DL
Hwu, P
Seth, P
Libutti, SK
Citation: Al. Feldman et al., Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice, CANCER RES, 60(6), 2000, pp. 1503-1506
Authors:
Bronte, V
Apolloni, E
Ronca, R
Zamboni, P
Overwijk, WW
Surman, DR
Restifo, NP
Zanovello, P
Citation: V. Bronte et al., Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo, CANCER RES, 60(2), 2000, pp. 253-258
Authors:
Leitner, WW
Ying, H
Driver, DA
Dubensky, TW
Restifo, NP
Citation: Ww. Leitner et al., Enhancement of tumor-specific immune response with plasmid DNA replicon vectors, CANCER RES, 60(1), 2000, pp. 51-55
Authors:
Bronte, V
Apolloni, E
Cabrelle, A
Ronca, R
Serafini, P
Zamboni, P
Restifo, NP
Zanovello, P
Citation: V. Bronte et al., Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable ofactivating or suppressing CD8(+) T cells, BLOOD, 96(12), 2000, pp. 3838-3846